Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc filed a Form 6‑K reporting its UK block listing six‑monthly return for the period from 1 May 2025 to 31 October 2025, detailing movements under three employee share plans.
Under the GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan, securities issued/allotted were 0, with a balance of unallotted securities of 115,518 at period end.
For the GlaxoSmithKline plc Share Save Plan 2012, securities issued/allotted were 134,547, leaving a balance of unallotted securities of 135,768 at period end.
For the GlaxoSmithKline plc Share Save Plan 2022, securities issued/allotted were 47,674, with a balance of unallotted securities of 904,117 at period end.
GSK plc reported share repurchases under its ongoing buyback. On 11 November 2025, the company bought 167,000 ordinary shares at prices between 1,791.50p and 1,825.00p, with a volume‑weighted average price of 1,807.35p. The shares will be held as treasury shares and the purchases were executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025. Since that date, GSK has purchased 8,496,000 shares.
Following these transactions, GSK holds 255,960,844 shares in treasury and has 4,059,467,530 shares in issue (excluding treasury shares). The total number of voting rights is 4,059,467,530, and the percentage of voting rights attributable to treasury shares is 6.31%.
GSK plc reported a buyback of 170,000 ordinary shares on 10 November 2025 under its existing programme via BNP Paribas SA. Prices ranged from 1,753.50p to 1,779.00p per share, with a volume‑weighted average price of 1,768.72p.
Since 30 September 2025, GSK has purchased 8,329,000 ordinary shares. After this purchase, GSK holds 255,793,844 shares in treasury and has 4,059,634,530 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,059,634,530, and the percentage of voting rights attributable to treasury shares is 6.30%. Trades were executed on the London Stock Exchange and Cboe Europe order books.
GSK published provisional 2026 dividend timetable; dates are indicative and may change.
Q1: announce April 29, ex-div May 14 (ADS May 15), record May 15, DRIP June 18, payable July 9. Q2: announce July 29, ex-div August 13 (ADS August 14), record August 14, DRIP September 17, payable October 8. Q3: announce October 28, ex-div November 12 (ADS November 13), record November 13, DRIP December 14, payable January 7, 2027. Q4: announce February 3, 2027, ex-div February 18 (ADS February 19), record February 19, DRIP March 16, payable April 8, 2027.
GSK repurchased 170,000 ordinary shares on 07 November 2025 at a volume‑weighted average price of 1,772.64p (low 1,757.50p; high 1,788.50p) under its existing buyback programme via BNP Paribas SA. The shares will be held as treasury shares.
Since 30 September 2025, GSK has bought 8,159,000 shares. Following this transaction, it holds 255,623,844 shares in treasury and has 4,059,804,530 shares in issue (excluding treasury). Total voting rights are 4,059,804,530, and treasury shares represent 6.30% of voting rights.
GSK plc reported a buyback transaction executed through BNP Paribas SA, purchasing 170,000 ordinary shares on 06 November 2025 at a volume‑weighted average price of 1,778.72p (range: 1,769.50p–1,786.00p). The shares will be held as treasury shares and the trade forms part of the existing buyback programme under a non‑discretionary agreement announced on 30 September 2025. Since that date, GSK has purchased 7,989,000 shares.
After this purchase, GSK holds 255,453,844 shares in treasury and has 4,059,969,755 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,059,969,755, and the percentage of voting rights attributable to treasury shares is 6.29%.
GSK plc repurchased 170,000 ordinary shares on 05 November 2025 as part of its existing buyback programme, executed via BNP Paribas SA. Prices ranged from 1,779.00p to 1,798.00p with a volume‑weighted average price of 1,789.04p. The purchased shares will be held as treasury shares.
Since 30 September 2025, the company has purchased 7,819,000 ordinary shares. After this transaction, GSK holds 255,283,844 shares in treasury and has 4,060,139,755 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,060,139,755, and the percentage of voting rights attributable to treasury shares is 6.29 per cent.
GSK plc reported a routine share buyback under its existing programme. On 04 November 2025, the company repurchased 175,000 ordinary shares at prices between 1,747.00p and 1,790.00p, with a volume‑weighted average price of 1,768.39p. The shares will be held as Treasury shares.
The purchase was executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025. Since 30 September 2025, 7,649,000 shares have been bought. After this transaction, GSK holds 255,113,844 shares in treasury and has 4,060,309,755 shares in issue (excluding treasury). The total number of voting rights is 4,060,309,755, and the percentage of voting rights attributable to treasury shares is 6.28%.
GSK plc reported a routine share buyback under its non‑discretionary agreement with BNP Paribas SA. On 03 November 2025, the company purchased 170,500 ordinary shares of 31¼ pence each at a lowest price 1,758.50p, highest price 1,782.00p, and volume‑weighted average price (VWAP) 1,769.85p. The shares will be held as Treasury shares and form part of the existing buyback programme announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 7,474,000 ordinary shares. After the latest transaction, GSK holds 254,938,844 shares in treasury and has 4,060,484,755 ordinary shares in issue (excluding treasury). The total voting rights are 4,060,484,755, and the percentage of voting rights attributable to treasury shares is 6.28%.
GSK plc reported its monthly total voting rights and capital. As at 31 October 2025, the company had 4,315,423,599 Ordinary Shares of 31 ¼ pence each in issue, of which 254,768,344 were held in treasury. The resulting total number of voting rights is 4,060,655,255.
Shareholders may use this voting rights figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
